Novavax has beaten earnings estimates in 3 of the last 4 quarters with an average surprise exceeding 270%, and analysts project 53% upside to their target, but a 28% short interest and weak quality metrics leave the stock in high-risk territory.
Thesis pillars
- Quality And Moat Deficit→Stable
- Earnings Beat Streak And Upside→Stable
- Analyst Upside Vs High Short Interest→Stable
- +1 more pillar — see the Why tab for full reasoning
Novavax, Inc. (NVAX) Stock Analysis
Breakout setup · Inst Constrain edge
Healthcare · Biotechnology
Sell if holding. Engine safety override at $9.67: Quality below floor (2.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10 and A.R:R 1.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 28%; Below-average business quality.
Novavax develops protein-based vaccines using its Matrix-M™ adjuvant and recombinant nanoparticle technology, with the FDA-approved Nuvaxovid™ (COVID-19 Vaccine) commercialized by Sanofi beginning in 2025. Revenue comes from Sanofi milestone payments and royalties, APA... Read more
Sell if holding. Engine safety override at $9.67: Quality below floor (2.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10 and A.R:R 1.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 28%; Below-average business quality. Chart setup: Golden cross, above all MAs, RSI 62, MACD bullish. Score 5.2/10, moderate confidence.
Passes 8/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 33d clear, semi cycle peak clear, materials cycle peak clear). Suitability: speculative.
About Novavax, Inc.
About Novavax, Inc.
Novavax's FDA-approved COVID-19 Vaccine, Nuvaxovid, received BLA approval in May 2025 for adults 65 and older and high-risk individuals aged 12 through 64, then was transferred to Sanofi under the Sanofi CLA in November 2025. The company reported net income of $440.3 million for fiscal year 2025, driven largely by $575.7 million in deferred revenue recognized upon termination of the Canada APA in March 2025. Matrix-M adjuvant licensing to Sanofi and, since January 2026, Pfizer, defines the forward revenue strategy.
Novavax earns revenue through product deliveries under remaining APA obligations — including $133.9 million under the Australia APA and $225.0 million under Gavi — alongside milestones and royalties from the Sanofi CLA, where the remaining COVID-19 milestone is $75 million contingent on completing technology transfer of the manufacturing process. In January 2026, a license agreement with Pfizer provided a $30 million upfront payment plus up to $500 million in development and sales milestones with tiered mid-single-digit royalties. Serum Institute of India manufactures the R21/Matrix-M adjuvant malaria vaccine, which reached 24 countries by February 2026 and pays Novavax royalties in the single- to low-double-digit range for 15 years per country. Takeda holds an exclusive Japan license for the COVID-19 Vaccine under the Amended Takeda CLA, which generated $40.9 million of license revenue in 2025.
Show full overview
The Sanofi CLA structures Novavax's primary commercial revenue pathway: up to $350 million in COVID-19 milestones (with $75 million remaining, contingent on technology transfer completion) plus up to $350 million in CIC development and launch milestones. If Sanofi fails to advance licensed products or technology transfer is delayed, milestone payments could be forfeited and the agreement may be terminated. The Australia APA also carries up to $92.5 million in deferred revenue refundable if delivery or regulatory approval deadlines are missed; Novavax withdrew its Australian vaccine application in the third quarter of 2025 after TGA recommendations, and discussions with Australia are ongoing.
See also: Healthcare · Biotechnology
From Novavax, Inc.'s most recent 10-K filing, extracted June 11, 2026.
Recent developments
updated 2026-07-06Recent Developments — Novavax, Inc.
Latest news
- NEWS U.S. FDA Advisers Vote In Favor Of Recommending Covid Vaccines Target JN.1 Lineage XFG Variant For 2026-27 Campaign — benzinga May 28, 2026 positive
- NEWS Hantavirus Scare Sparks Vaccine Stock Rally: Moderna, Novavax Climb — benzinga May 11, 2026 positive
- NEWS What's Going On With Novavax Stock On Friday? — benzinga May 8, 2026 neutral
- NEWS Earnings Scheduled For May 6, 2026 — benzinga May 6, 2026 neutral
- NEWS TD Cowen Maintains Hold on Novavax, Raises Price Target to $9 — benzinga May 6, 2026 neutral
Generated 2026-07-06T06:50:34Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMcounterpartySanofi10-K Item 1: 'In 2025 and continuing during the term of the Sanofi CLA, Sanofi will lead commercialization efforts for our COVID-19 Vaccine (Nuvaxovid™).'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Volatile — 5.8% daily ATR makes tight stops impractical. Position-size conservatively.static
Unprofitable operations — net margin -14.7%. Quality floor flags this regardless of sector context.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $9.67: Quality below floor (2.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10 and A.R:R 1.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 28%; Below-average business quality. Chart setup: Golden cross, above all MAs, RSI 62, MACD bullish. Prior stop was $9.06. Score 5.2/10, moderate confidence.
Take-profit target: $12.28 (+26.1% upside). Prior stop was $9.06. Stop-loss: $9.06.
Quality below floor (2.8 < 4.0).
Novavax, Inc. trades at a P/E of N/A (forward -18.0). TrendMatrix value score: 7.3/10. Verdict: Sell.
15 analysts cover NVAX with a consensus score of 3.7/5. Average price target: $14.
What does Novavax, Inc. do?Novavax develops protein-based vaccines using its Matrix-M™ adjuvant and recombinant nanoparticle technology, with the...
Novavax develops protein-based vaccines using its Matrix-M™ adjuvant and recombinant nanoparticle technology, with the FDA-approved Nuvaxovid™ (COVID-19 Vaccine) commercialized by Sanofi beginning in 2025. Revenue comes from Sanofi milestone payments and royalties, APA deliveries, and Matrix-M adjuvant licensing including a $30 million upfront from Pfizer in January 2026.